Physician profile
Sofia Qadir
NPI 1659442515
$7,277.93
in general payments reported to CMS, 2019-2025
19 companies · $1,187 in 2025
The $1,187 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $257 · 2021: $127 · 2022: $1,500 · 2023: $1,728 · 2024: $2,102 · 2025: $1,187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,989 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,988.70 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,182.67 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $976.77 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $894.96 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $878.09 | 2021-2025 | |
| Axsome Therapeutics, INC. | $839.31 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $568.94 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $443.62 | 2022-2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $399.73 | 2022-2025 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.19 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.70 | 2022-2023 | |
| Allergan, INC. | $141.87 | 2020 | |
| Luye Pharma (USA) Ltd. | $124.99 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $121.83 | 2025 | Xelstrym |
| Vanda Pharmaceuticals INC. | $91.08 | 2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $34.93 | 2022-2023 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $29.90 | 2023 | Quviviq |
| Bioxcel Therapeutics, INC. | $24.52 | 2024 | Igalmi |
| Brainsway USA INC | $15.05 | 2022 | |
| Validus Pharmaceuticals LLC | $0.78 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Qadir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.